bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table from Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay
Authors: Hu Chunling , Susswein Lisa R. , Roberts Maegan E. , Yang Hana , Marshall Megan L. , Hiraki Susan , Berkofsky-Fessler Windy , Gupta Sounak , Shen Wei , Dunn Carolyn A. , Huang Huaizhi , Na Jie , Domchek Susan M. , Yadav Siddhartha , Monteiro Alvaro N.A. , Polley Eric C. , Hart Steven N. , Hruska Kathleen S. , Couch Fergus J.
Published: April 2023

Supplementary Table from Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay
Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Authors: Radovich Milan , Solzak Jeffrey P. , Wang Chao J. , Hancock Bradley A. , Badve Sunil , Althouse Sandra K. , Bray Steven M. , Storniolo Anna Maria V. , Ballinger Tarah J. , Schneider Bryan P. , Miller Kathy D.
Published: April 2023

Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Supplementary Table from Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
Authors: Li Yimei , Hwang Wei-Ting , Maude Shannon L. , Teachey David T. , Frey Noelle V. , Myers Regina M. , Barz Leahy Allison , Liu Hongyan , Porter David L. , Grupp Stephan A. , Shaw Pamela A.
Published: April 2023

Supplementary Table from Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
Supplementary Data from Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
Authors: Li Yimei , Hwang Wei-Ting , Maude Shannon L. , Teachey David T. , Frey Noelle V. , Myers Regina M. , Barz Leahy Allison , Liu Hongyan , Porter David L. , Grupp Stephan A. , Shaw Pamela A.
Published: April 2023

Supplementary Data from Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Authors: Chen Li , Jiang Yi-Zhou , Wu Song-Yang , Wu Jiong , Di Gen-Hong , Liu Guang-Yu , Yu Ke-Da , Fan Lei , Li Jun-Jie , Hou Yi-Feng , Hu Zhen , Chen Can-Ming , Huang Xiao-Yan , Cao A-Yong , Hu Xin , Zhao Shen , Ma Xiao-Yan , Xu Ying , Sun Xiang-Jie , Chai Wen-Jun , Guo Xiaomao , Chen Xizi , Xu Yanhui , Zhu Xiao-Yu , Zou Jian-Jun , Yang Wen-Tao , Wang Zhong-Hua , Shao Zhi-Ming
Published: April 2023

Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Table from Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
Authors: Hagner Patrick R. , Chiu Hsiling , Chopra Vivek S. , Colombo Martino , Patel Nisha , Estevez Maria Ortiz , Waldman Michelle F. , Loos Remco , Towfic Fadi , Gandhi Anita K.
Published: April 2023

Supplementary Table from Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
Authors: Tesileanu C. Mircea S. , Sanson Marc , Wick Wolfgang , Brandes Alba A. , Clement Paul M. , Erridge Sara C. , Vogelbaum Michael A. , Nowak Anna K. , Baurain Jean-Francois , Mason Warren P. , Wheeler Helen , Chinot Olivier L. , Gill Sanjeev , Griffin Matthew , Rogers Leland , Taal Walter , Rudà Roberta , Weller Michael , McBain Catherine , van Linde Myra E. , Aldape Kenneth , Jenkins Robert B. , Kros Johan M. , Wesseling Pieter , von Deimling Andreas , Hoogstrate Youri , de Heer Iris , Atmodimedjo Peggy N. , Dubbink Hendrikus J. , Brouwer Rutger W.W. , van IJcken Wilfred F.J. , Cheung Kin Jip , Golfinopoulos Vassilis , Baumert Brigitta G. , Gorlia Thierry , French Pim J. , van den Bent Martin J.
Published: April 2023

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
Supplementary Figure from Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
Authors: Hagner Patrick R. , Chiu Hsiling , Chopra Vivek S. , Colombo Martino , Patel Nisha , Estevez Maria Ortiz , Waldman Michelle F. , Loos Remco , Towfic Fadi , Gandhi Anita K.
Published: April 2023

Supplementary Figure from Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
Supplementary Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
Authors: Tesileanu C. Mircea S. , Sanson Marc , Wick Wolfgang , Brandes Alba A. , Clement Paul M. , Erridge Sara C. , Vogelbaum Michael A. , Nowak Anna K. , Baurain Jean-Francois , Mason Warren P. , Wheeler Helen , Chinot Olivier L. , Gill Sanjeev , Griffin Matthew , Rogers Leland , Taal Walter , Rudà Roberta , Weller Michael , McBain Catherine , van Linde Myra E. , Aldape Kenneth , Jenkins Robert B. , Kros Johan M. , Wesseling Pieter , von Deimling Andreas , Hoogstrate Youri , de Heer Iris , Atmodimedjo Peggy N. , Dubbink Hendrikus J. , Brouwer Rutger W.W. , van IJcken Wilfred F.J. , Cheung Kin Jip , Golfinopoulos Vassilis , Baumert Brigitta G. , Gorlia Thierry , French Pim J. , van den Bent Martin J.
Published: April 2023

Supplementary Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
Supplementary Data from Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
Authors: Hagner Patrick R. , Chiu Hsiling , Chopra Vivek S. , Colombo Martino , Patel Nisha , Estevez Maria Ortiz , Waldman Michelle F. , Loos Remco , Towfic Fadi , Gandhi Anita K.
Published: April 2023

Supplementary Data from Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
Supplementary Table from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Authors: Markowski Mark C. , Tutrone Ronald , Pieczonka Christopher , Barnette K. Gary , Getzenberg Robert H. , Rodriguez Domingo , Steiner Mitchell S. , Saltzstein Daniel R. , Eisenberger Mario A. , Antonarakis Emmanuel S.
Published: April 2023

Supplementary Table from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Supplementary Figure from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
Authors: Yurchenko Andrey A. , Pop Oltin T. , Ighilahriz Meriem , Padioleau Ismael , Rajabi Fatemeh , Sharpe Hayley J. , Poulalhon Nicolas , Dreno Brigitte , Khammari Amir , Delord Marc , Alberti Antonio , Soufir Nadem , Battistella Maxime , Mourah Samia , Bouquet Fanny , Savina Ariel , Besse Andrej , Mendez-Lopez Max , Grange Florent , Monestier Sandrine , Mortier Laurent , Meyer Nicolas , Dutriaux Caroline , Robert Caroline , Saiag Philippe , Herms Florian , Lambert Jerome , de Sauvage Frederic J. , Dumaz Nicolas , Flatz Lukas , Basset-Seguin Nicole , Nikolaev Sergey I.
Published: April 2023

Supplementary Figure from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
Supplementary Data from Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Authors: Löffler Markus W. , Gori Stefania , Izzo Francesco , Mayer-Mokler Andrea , Ascierto Paolo A. , Königsrainer Alfred , Ma Yuk Ting , Sangro Bruno , Francque Sven , Vonghia Luisa , Inno Alessandro , Avallone Antonio , Ludwig Jörg , Alcoba Diego Duarte , Flohr Christian , Aslan Katrin , Mendrzyk Regina , Schuster Heiko , Borrelli Marco , Valmori Danila , Chaumette Tanguy , Heidenreich Regina , Gouttefangeas Cécile , Forlani Greta , Tagliamonte Maria , Fusco Caterina , Penta Roberta , Iñarrairaegui Mercedes , Gnad-Vogt Ulrike , Reinhardt Carsten , Weinschenk Toni , Accolla Roberto S. , Singh-Jasuja Harpreet , Rammensee Hans-Georg , Buonaguro Luigi
Published: April 2023

Supplementary Data from Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Supplementary Table from Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
Authors: Yukami Hiroki , Kawazoe Akihito , Lin Yi-Tzu , Koyama Shohei , Fukuoka Shota , Hara Hiroki , Takahashi Naoki , Kojima Takashi , Asayama Masako , Yoshii Takako , Bando Hideaki , Kotani Daisuke , Nakamura Yoshiaki , Kuboki Yasutoshi , Mishima Saori , Wakabayashi Masashi , Kuwata Takeshi , Goto Masahiro , Higuchi Kazuhide , Yoshino Takayuki , Doi Toshihiko , Nishikawa Hiroyoshi , Shitara Kohei
Published: April 2023

Supplementary Table from Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
Supplementary Figure from Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
Authors: Yukami Hiroki , Kawazoe Akihito , Lin Yi-Tzu , Koyama Shohei , Fukuoka Shota , Hara Hiroki , Takahashi Naoki , Kojima Takashi , Asayama Masako , Yoshii Takako , Bando Hideaki , Kotani Daisuke , Nakamura Yoshiaki , Kuboki Yasutoshi , Mishima Saori , Wakabayashi Masashi , Kuwata Takeshi , Goto Masahiro , Higuchi Kazuhide , Yoshino Takayuki , Doi Toshihiko , Nishikawa Hiroyoshi , Shitara Kohei
Published: April 2023

Supplementary Figure from Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
Supplementary Figure from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
Authors: Szabados Bernadett , Ponz-Sarvisé Mariano , Machado Robson , Saldana Diego , Kadel Edward E. , Banchereau Romain , Bouquet Fanny , Garmhausen Marius , Powles Thomas , Schröder Carsten
Published: April 2023

Supplementary Figure from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
Supplementary Figure from Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
Authors: Sato Jun , Shimizu Toshio , Koyama Takafumi , Iwasa Satoru , Shimomura Akihiko , Kondo Shunsuke , Kitano Shigehisa , Yonemori Kan , Fujiwara Yutaka , Tamura Kenji , Suzuki Takuya , Takase Takao , Nagai Reiko , Yamaguchi Kohei , Semba Taro , Zhao Zi-Ming , Ren Min , Yamamoto Noboru
Published: April 2023

Supplementary Figure from Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
Supplementary Figure from Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Authors: Ng Wai-Tong , Choi Cheuk-Wai , But Barton , Ngan Roger K.C. , Tung Stewart , Cheng Ashley C. , Kwong Dora L.W. , Lu Tai-Xiang , Chan Anthony T.C. , Yiu Harry , Lee Sarah , Wong Frank , Yuen Kam-Tong , Chappell Richard J. , Lee Anne W.M.
Published: April 2023

Supplementary Figure from Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
Authors: Fucikova Jitka , Hensler Michal , Kasikova Lenka , Lanickova Tereza , Pasulka Josef , Rakova Jana , Drozenova Jana , Fredriksen Tessa , Hraska Marek , Hrnciarova Tereza , Sochorova Klara , Rozkova Daniela , Sojka Ludek , Dundr Pavel , Laco Jan , Brtnicky Tomas , Praznovec Ivan , Halaska Michael J. , Rob Lukas , Ryska Ales , Coosemans An , Vergote Ignace , Cibula David , Bartunkova Jirina , Galon Jérôme , Galluzzi Lorenzo , Spisek Radek
Published: April 2023

Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
Supplementary Table from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Authors: Chakraborty Goutam , Nandakumar Subhiksha , Hirani Rahim , Nguyen Bastien , Stopsack Konrad H. , Kreitzer Christoph , Rajanala Sai Harisha , Ghale Romina , Mazzu Ying Z. , Pillarsetty Naga Vara Kishore , Lee Gwo-Shu Mary , Scher Howard I. , Morris Michael J. , Traina Tiffany , Razavi Pedram , Abida Wassim , Durack Jeremy C. , Solomon Stephen B. , Vander Heiden Matthew G. , Mucci Lorelei A. , Wibmer Andreas G. , Schultz Nikolaus , Kantoff Philip W.
Published: April 2023

Supplementary Table from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Authors: Chakraborty Goutam , Nandakumar Subhiksha , Hirani Rahim , Nguyen Bastien , Stopsack Konrad H. , Kreitzer Christoph , Rajanala Sai Harisha , Ghale Romina , Mazzu Ying Z. , Pillarsetty Naga Vara Kishore , Lee Gwo-Shu Mary , Scher Howard I. , Morris Michael J. , Traina Tiffany , Razavi Pedram , Abida Wassim , Durack Jeremy C. , Solomon Stephen B. , Vander Heiden Matthew G. , Mucci Lorelei A. , Wibmer Andreas G. , Schultz Nikolaus , Kantoff Philip W.
Published: April 2023

Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Supplementary Table from Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy
Authors: Lee Sunyoung , Shroff Rachna T. , Makawita Shalini , Xiao Lianchun , Danner De Armas Anaemy , Bhosale Priya , Reddy Kavitha , Shalaby Ahmed , Raghav Kanwal , Pant Shubham , Wolff Robert A. , Javle Milind
Published: April 2023

Supplementary Table from Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy
Supplementary Figure from Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy
Authors: Lee Sunyoung , Shroff Rachna T. , Makawita Shalini , Xiao Lianchun , Danner De Armas Anaemy , Bhosale Priya , Reddy Kavitha , Shalaby Ahmed , Raghav Kanwal , Pant Shubham , Wolff Robert A. , Javle Milind
Published: April 2023

Supplementary Figure from Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy
Supplementary Data from VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
Authors: Lindeman Geoffrey J. , Fernando Tharu M. , Bowen Rebecca , Jerzak Katarzyna J. , Song Xinni , Decker Thomas , Boyle Frances , McCune Steve , Armstrong Anne , Shannon Catherine , Bertelli Gianfilippo , Chang Ching-Wei , Desai Rupal , Gupta Kushagra , Wilson Timothy R. , Flechais Aulde , Bardia Aditya
Published: April 2023

Supplementary Data from VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Authors: Yap Timothy A. , Gainor Justin F. , Callahan Margaret K. , Falchook Gerald S. , Pachynski Russell K. , LoRusso Patricia , Kummar Shivaani , Gibney Geoffrey T. , Burris Howard A. , Tykodi Scott S. , Rahma Osama E. , Seiwert Tanguy Y. , Papadopoulos Kyriakos P. , Blum Murphy Mariela , Park Haeseong , Hanson Amanda , Hashambhoy-Ramsay Yasmin , McGrath Lara , Hooper Ellen , Xiao Xiaoying , Cohen Heather , Fan Martin , Felitsky Daniel , Hart Courtney , McComb Rachel , Brown Karen , Sepahi Ali , Jimenez Judith , Zhang Weidong , Baeck Johan , Laken Haley , Murray Richard , Trehu Elizabeth , Harvey Christopher J.
Published: April 2023

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Supplementary Figure from Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis
Authors: Berchuck Jacob E. , Baca Sylvan C. , McClure Heather M. , Korthauer Keegan , Tsai Harrison K. , Nuzzo Pier Vitale , Kelleher Kaitlin M. , He Monica , Steinharter John A. , Zacharia Soumya , Spisak Sandor , Seo Ji-Heui , Conteduca Vincenza , Elemento Olivier , Auh Joonghoon , Sigouros Michael , Corey Eva , Hirsch Michelle S. , Taplin Mary-Ellen , Choueiri Toni K. , Pomerantz Mark M. , Beltran Himisha , Freedman Matthew L.
Published: April 2023

Supplementary Figure from Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis
Supplementary Data from Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
Authors: Inaba Hiroto , van Oosterwijk Jolieke G. , Panetta John C. , Li Lie , Buelow Daelynn R. , Blachly James S. , Shurtleff Sheila , Pui Ching-Hon , Ribeiro Raul C. , Rubnitz Jeffrey E. , Pounds Stanley , Baker Sharyn D.
Published: April 2023

Supplementary Data from Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
Supplementary Data from Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis
Authors: Penel Nicolas , Bonvalot Sylvie , Bimbai André-Michel , Meurgey Alexandra , Le Loarer François , Salas Sébastien , Piperno-Neumann Sophie , Chevreau Christine , Boudou-Rouquette Pascaline , Dubray-Longeras Pascale , Kurtz Jean-Emmanuel , Guillemet Cécile , Bompas Emmanuelle , Italiano Antoine , Le Cesne Axel , Orbach Daniel , Thery Julien , Le Deley Marie-Cécile , Blay Jean-Yves , Mir Olivier
Published: April 2023

Supplementary Data from Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis
Supplementary Data from Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC
Authors: Arend Rebecca C. , Scalise Carly B. , Gordon Emily R. , Davis Allison M. , Foxall McKenzie E. , Johnston Bobbi E. , Crossman David K. , Cooper Sara J.
Published: April 2023

Supplementary Data from Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC
Supplementary Data from Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
Authors: Sabari Joshua K. , Velcheti Vamsidhar , Shimizu Kazuhide , Strickland Matthew R. , Heist Rebecca S. , Singh Mohini , Nayyar Naema , Giobbie-Hurder Anita , Digumarthy Subba R. , Gainor Justin F. , Rajan Anant P. , Nieblas-Bedolla Edwin , Burns Aaron C. , Hallin Jill , Olson Peter , Christensen James G. , Kurz Sylvia C. , Brastianos Priscilla K. , Wakimoto Hiroaki
Published: April 2023

Supplementary Data from Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
Supplementary Table from A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis
Authors: Colombo Chiara , Fiore Marco , Grignani Giovanni , Tolomeo Francesco , Merlini Alessandra , Palassini Elena , Collini Paola , Stacchiotti Silvia , Casali Paolo Giovanni , Perrone Federica , Mariani Luigi , Gronchi Alessandro
Published: April 2023

Supplementary Table from A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis
Supplementary Table from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Authors: Hemming Matthew L. , Bhola Patrick , Loycano Michael A. , Anderson Justin A. , Taddei Madeleine L. , Doyle Leona A. , Lavrova Elizaveta , Andersen Jessica L. , Klega Kelly S. , Benson Morgan R. , Crompton Brian D. , Raut Chandrajit P. , George Suzanne , Letai Anthony , Demetri George D. , Sicinska Ewa
Published: April 2023

Supplementary Table from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Supplementary Figure from Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
Authors: Xia Youli , He Xiaping , Renshaw Lorna , Martinez-Perez Carlos , Kay Charlene , Gray Mark , Meehan James , Parker Joel S. , Perou Charles M. , Carey Lisa A. , Dixon J. Michael , Turnbull Arran
Published: April 2023

Supplementary Figure from Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
Supplementary Table from First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Authors: Diamond Jennifer R. , Boni Valentina , Lim Emerson , Nowakowski Grzegorz , Cordoba Raul , Morillo Daniel , Valencia Ray , Genvresse Isabelle , Merz Claudia , Boix Oliver , Frigault Melanie M. , Greer Joy M. , Hamdy Ahmed M. , Huang Xin , Izumi Raquel , Wong Harvey , Moreno Victor
Published: April 2023

Supplementary Table from First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Supplementary Data from Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
Authors: Xia Youli , He Xiaping , Renshaw Lorna , Martinez-Perez Carlos , Kay Charlene , Gray Mark , Meehan James , Parker Joel S. , Perou Charles M. , Carey Lisa A. , Dixon J. Michael , Turnbull Arran
Published: April 2023

Supplementary Data from Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
Supplementary Table from Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
Authors: Durinikova Erika , Reilly Nicole M. , Buzo Kristi , Mariella Elisa , Chilà Rosaria , Lorenzato Annalisa , Dias João M. L. , Grasso Gaia , Pisati Federica , Lamba Simona , Corti Giorgio , Degasperi Andrea , Cancelliere Carlotta , Mauri Gianluca , Andrei Pietro , Linnebacher Michael , Marsoni Silvia , Siena Salvatore , Sartore-Bianchi Andrea , Nik-Zainal Serena , Di Nicolantonio Federica , Bardelli Alberto , Arena Sabrina
Published: April 2023

Supplementary Table from Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
Supplementary Figure from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Authors: Sudha Parvathi , Ahsan Aarif , Ashby Cody , Kausar Tasneem , Khera Akhil , Kazeroun Mohammad H. , Hsu Chih-Chao , Wang Lin , Fitzsimons Evelyn , Salminen Outi , Blaney Patrick , Czader Magdalena , Williams Jonathan , Abu Zaid Mohammad I. , Ansari-Pour Naser , Yong Kwee L. , van Rhee Frits , Pierceall William E. , Morgan Gareth J. , Flynt Erin , Gooding Sarah , Abonour Rafat , Ramasamy Karthik , Thakurta Anjan , Walker Brian A.
Published: April 2023

Supplementary Figure from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Supplementary Data from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells
Authors: Goff Peter H. , Riolobos Laura , LaFleur Bonnie J. , Spraker Matthew B. , Seo Y. David , Smythe Kimberly S. , Campbell Jean S. , Pierce Robert H. , Zhang Yuzheng , He Qianchuan , Kim Edward Y. , Schaub Stephanie K. , Kane Gabrielle M. , Mantilla Jose G. , Chen Eleanor Y. , Ricciotti Robert , Thompson Matthew J. , Cranmer Lee D. , Wagner Michael J. , Loggers Elizabeth T. , Jones Robin L. , Murphy Erin , Blumenschein Wendy M. , McClanahan Terrill K. , Earls Jon , Flanagan Kevin C. , LaFranzo Natalie A. , Kim Teresa S. , Pollack Seth M.
Published: April 2023

Supplementary Data from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells
Supplementary Data from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Authors: Sudha Parvathi , Ahsan Aarif , Ashby Cody , Kausar Tasneem , Khera Akhil , Kazeroun Mohammad H. , Hsu Chih-Chao , Wang Lin , Fitzsimons Evelyn , Salminen Outi , Blaney Patrick , Czader Magdalena , Williams Jonathan , Abu Zaid Mohammad I. , Ansari-Pour Naser , Yong Kwee L. , van Rhee Frits , Pierceall William E. , Morgan Gareth J. , Flynt Erin , Gooding Sarah , Abonour Rafat , Ramasamy Karthik , Thakurta Anjan , Walker Brian A.
Published: April 2023

Supplementary Data from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Supplementary Table from Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Authors: Seppälä Toni T. , Zimmerman Jacquelyn W. , Suri Reecha , Zlomke Haley , Ivey Gabriel D. , Szabolcs Annamaria , Shubert Christopher R. , Cameron John L. , Burns William R. , Lafaro Kelly J. , He Jin , Wolfgang Christopher L. , Zou Ying S. , Zheng Lei , Tuveson David A. , Eshlemann James R. , Ryan David P. , Kimmelman Alec C. , Hong Theodore S. , Ting David T. , Jaffee Elizabeth M. , Burkhart Richard A.
Published: April 2023

Supplementary Table from Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Supplementary Figure from Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Authors: Seppälä Toni T. , Zimmerman Jacquelyn W. , Suri Reecha , Zlomke Haley , Ivey Gabriel D. , Szabolcs Annamaria , Shubert Christopher R. , Cameron John L. , Burns William R. , Lafaro Kelly J. , He Jin , Wolfgang Christopher L. , Zou Ying S. , Zheng Lei , Tuveson David A. , Eshlemann James R. , Ryan David P. , Kimmelman Alec C. , Hong Theodore S. , Ting David T. , Jaffee Elizabeth M. , Burkhart Richard A.
Published: April 2023

Supplementary Figure from Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Supplementary Table from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Authors: Cheng Vinton W.T. , de Pennington Nicholas , Zakaria Rasheed , Larkin James R. , Serres Sébastien , Sarkar Manjima , Kirkman Matthew A. , Bristow Claire , Croal Paula , Plaha Puneet , Campo Leticia , Chappell Michael A. , Lord Simon , Jenkinson Michael D. , Middleton Mark R. , Sibson Nicola R.
Published: April 2023

Supplementary Table from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Supplementary Data from Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Authors: Seppälä Toni T. , Zimmerman Jacquelyn W. , Suri Reecha , Zlomke Haley , Ivey Gabriel D. , Szabolcs Annamaria , Shubert Christopher R. , Cameron John L. , Burns William R. , Lafaro Kelly J. , He Jin , Wolfgang Christopher L. , Zou Ying S. , Zheng Lei , Tuveson David A. , Eshlemann James R. , Ryan David P. , Kimmelman Alec C. , Hong Theodore S. , Ting David T. , Jaffee Elizabeth M. , Burkhart Richard A.
Published: April 2023

Supplementary Data from Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Supplementary Data from Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas
Authors: Gaydosik Alyxzandria M. , Stonesifer Connor J. , Khaleel Alexandra E. , Geskin Larisa J. , Fuschiotti Patrizia
Published: April 2023

Supplementary Data from Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas
Supplementary Table from Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment
Authors: Autio Matias , Leivonen Suvi-Katri , Brück Oscar , Karjalainen-Lindsberg Marja-Liisa , Pellinen Teijo , Leppä Sirpa
Published: April 2023

Supplementary Table from Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment
Supplementary Figure from Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment
Authors: Autio Matias , Leivonen Suvi-Katri , Brück Oscar , Karjalainen-Lindsberg Marja-Liisa , Pellinen Teijo , Leppä Sirpa
Published: April 2023

Supplementary Figure from Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment
Supplementary Figure from Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers
Authors: Gazinska Patrycja , Milton Charlotte , Iacovacci Jacopo , Ward Joseph , Buus Richard , Alaguthurai Thanussuyah , Graham Rosalind , Akarca Ayse , Lips Esther , Naidoo Kalnisha , Wesseling Jelle , Marafioti Teresa , Cheang Maggie , Gillett Cheryl , Wu Yin , Khan Aadil , Melcher Alan , Salgado Roberto , Dowsett Mitch , Tutt Andrew , Roxanis Ioannis , Haider Syed , Irshad Sheeba
Published: April 2023

Supplementary Figure from Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers
Supplemental Table 3 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Authors: Wainberg Zev A. , Singh Arun S. , Konecny Gottfried E. , McCann Kelly E. , Hecht J. Randolph , Goldman Jonathan , Chmielowski Bartosz , Finn Richard S. , O'Brien Neil , Von Euw Erika , Price Megan M. , Martinez Diego , Yonemoto Lisa , Brennan Meghan , Glaspy John A. , Slamon Dennis J.
Published: April 2023

Supplemental Table 3
Supplemental Table 2 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Authors: Wainberg Zev A. , Singh Arun S. , Konecny Gottfried E. , McCann Kelly E. , Hecht J. Randolph , Goldman Jonathan , Chmielowski Bartosz , Finn Richard S. , O'Brien Neil , Von Euw Erika , Price Megan M. , Martinez Diego , Yonemoto Lisa , Brennan Meghan , Glaspy John A. , Slamon Dennis J.
Published: April 2023

Supplemental Table 2
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Authors: Wang Feng , He Ming-Ming , Xiao Jian , Zhang Yan-Qiao , Yuan Xiang-Lin , Fang Wei-Jia , Zhang Yan , Wang Wei , Hu Xiao-Hua , Ma Zhi-Gang , Yao Yi-Chen , Zhuang Zhi-Xiang , Zhou Fu-Xiang , Ying Jie-Er , Yuan Ying , Zou Qing-Feng , Guo Zeng-Qing , Wu Xiang-Yuan , Jin Ying , Mai Zong-Jiong , Wang Zhi-Qiang , Qiu Hong , Guo Ying , Shi Si-Mei , Chen Shuang-Zhen , Luo Hui-Yan , Zhang Dong-Sheng , Wang Feng-Hua , Li Yu-Hong , Xu Rui-Hua
Published: April 2023

Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Related to Figure 2 - SMS-CTR
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Authors: Wang Feng , He Ming-Ming , Xiao Jian , Zhang Yan-Qiao , Yuan Xiang-Lin , Fang Wei-Jia , Zhang Yan , Wang Wei , Hu Xiao-Hua , Ma Zhi-Gang , Yao Yi-Chen , Zhuang Zhi-Xiang , Zhou Fu-Xiang , Ying Jie-Er , Yuan Ying , Zou Qing-Feng , Guo Zeng-Qing , Wu Xiang-Yuan , Jin Ying , Mai Zong-Jiong , Wang Zhi-Qiang , Qiu Hong , Guo Ying , Shi Si-Mei , Chen Shuang-Zhen , Luo Hui-Yan , Zhang Dong-Sheng , Wang Feng-Hua , Li Yu-Hong , Xu Rui-Hua
Published: April 2023

Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Data File S4 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Sample Sizes
Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Related to Figure 1D
Supplementary Figure from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Authors: Yin Yanping , Athanasiadis Paschalis , Karlsen Linda , Urban Aleksandra , Xu Haifeng , Murali Ishwarya , Fernandes Stacey M. , Arribas Alberto J. , Hilli Abdul K. , Taskén Kjetil , Bertoni Francesco , Mato Anthony R. , Normant Emmanuel , Brown Jennifer R. , Tjønnfjord Geir E. , Aittokallio Tero , Skånland Sigrid S.
Published: April 2023

Supplementary Figure from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Supplementary Table S1 from CD8+ Tumor-Infiltrating Lymphocyte Abundance Is a Positive Prognostic Indicator in Nasopharyngeal Cancer
Authors: Shi Wei , Fijardo Mackenzie , Bruce Jeff P. , Su Jie , Xu Wei , Bell Rachel , Bissey Pierre-Antoine , Hui Angela B.Y. , Waldron John , Pugh Trevor J. , Yip Kenneth W. , Liu Fei-Fei
Published: April 2023

Table S1: Patient Radiotherapy Information and Multivariate Analysis.
Supplementary Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Authors: Park Wungki , O'Connor Catherine A. , Bandlamudi Chaitanya , Forman Daniella , Chou Joanne F. , Umeda Shigeaki , Reyngold Marsha , Varghese Anna M. , Keane Fergus , Balogun Fiyinfolu , Yu Kenneth H. , Kelsen David P. , Crane Christopher , Capanu Marinela , Iacobuzio-Donahue Christine , O'Reilly Eileen M.
Published: April 2023

Supplementary Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Supplementary Figures S1-S5 from CD8+ Tumor-Infiltrating Lymphocyte Abundance Is a Positive Prognostic Indicator in Nasopharyngeal Cancer
Authors: Shi Wei , Fijardo Mackenzie , Bruce Jeff P. , Su Jie , Xu Wei , Bell Rachel , Bissey Pierre-Antoine , Hui Angela B.Y. , Waldron John , Pugh Trevor J. , Yip Kenneth W. , Liu Fei-Fei
Published: April 2023

Table S1: Patient Radiotherapy Information and Multivariate Analysis.
Figure S1: Workflow of evaluation of T cell receptor (TCR) rearrangement and ESTIMATE immune score from RNA-sequencing data, and the expression of tumor-infiltrating lymphocytes (TILs) in NPC patients.
Figure S2: The correlation of ESTIMATE immune score with rearranged TCR reads and CD8+ TILs.
Figure S3: The correlation of CIBERSORT and TIMER 2.0 with rearranged TCR reads and CD8+ TILs.
Figure S4: The distribution of TILs in NPC samples.
Figure S5: Clinical impact of CD8+ TILs in the combined cohort of NPC patients.
Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
Authors: Mao Lili , Fang Meiyu , Chen Yu , Wei Xiaoting , Cao Jun , Lin Jing , Zhang Peng , Chen Ling , Cao Xiao , Chen Yujun , Guo Jun , Si Lu
Published: April 2023

Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
Supplementary Methods from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
Authors: Paudel Sarita , Warner Benjamin E. , Wang Renwei , Adams-Haduch Jennifer , Reznik Alex S. , Dou Jason , Huang Yufei , Gao Yu-Tang , Koh Woon-Puay , Bäckerholm Alan , Yuan Jian-Min , Shair Kathy H.Y.
Published: April 2023

EBV Expression Library; Multiplex Immunoblot Assay; Conservation Plots
Supplementary Figure S2 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
Authors: Paudel Sarita , Warner Benjamin E. , Wang Renwei , Adams-Haduch Jennifer , Reznik Alex S. , Dou Jason , Huang Yufei , Gao Yu-Tang , Koh Woon-Puay , Bäckerholm Alan , Yuan Jian-Min , Shair Kathy H.Y.
Published: April 2023

Detection of EBV-specific IgG in sera from incident NPC cases and healthy controls in the SCHS cohort.
Heatmap depicting IgG heavy and light chain-specific (IgGH+L) detection values from 20 incident NPC case-control pairs and the data is represented similarly to Fig 2 with Fisher’s exact test identifying proteins (bolded) that discriminate case from controls and denoted *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. IgGH+L represents total antibody responses because light chains common to all antibody isotypes are detected.
Supplementary Figure from SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer
Authors: Swami Umang , Graf Ryon P. , Nussenzveig Roberto H. , Fisher Virginia , Tukachinsky Hanna , Schrock Alexa B. , Li Gerald , Ross Jeffrey S. , Sayegh Nicolas , Tripathi Nishita , Mathew Thomas Vinay , Oxnard Geoffrey R. , Antonarakis Emmanuel S. , Agarwal Neeraj
Published: April 2023

Supplementary Figure from SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer
Supplementary Figure 5 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Authors: Sathe Anuja , Mason Kaishu , Grimes Susan M. , Zhou Zilu , Lau Billy T. , Bai Xiangqi , Su Andrew , Tan Xiao , Lee HoJoon , Suarez Carlos J. , Nguyen Quan , Poultsides George , Zhang Nancy R. , Ji Hanlee P.
Published: April 2023

Graphical representation of cell types identified in CODEX analysis in image data from respective patients.
Supplementary Tables S1-S8 from Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Authors: Vidal Joana , Fernández-Rodríguez Maria Concepción , Casadevall David , García-Alfonso Pilar , Páez David , Guix Marta , Alonso Vicente , Cano Maria Teresa , Santos Cristina , Durán Gema , Elez Elena , Manzano José Luís , Garcia-Carbonero Rocío , Ferreiro Reyes , Losa Ferran , Pineda Estela , Sastre Javier , Rivera Fernando , Bellosillo Beatriz , Tabernero Josep , Aranda Enrique , Salazar Ramon , Montagut Clara
Published: April 2023

Supplementary Tables 1-8
Supplementary Tables 1, 3, 5-7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

Supplementary Table 1. Somatic mutations of the patient's glioblastoma; Supplementary Table 2. See Excel File; Supplementary Table 3. Literature-derived, glioblastoma-associated TAAs; Supplementary Table 4. See Excel File; Supplementary Table 5. Over-/highly expressed genes that were chosen for the design of vaccine peptides; Supplementary Table 6. Peptide cocktails for vaccination; Supplementary Table 7. Antibodies for imaging mass cytometry.
Supplementary Figure from STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer
Authors: Qureshy Zoya , Li Hua , Zeng Yan , Rivera Jose , Cheng Ning , Peterson Christopher N. , Kim Mi-Ok , Ryan William R. , Ha Patrick K. , Bauman Julie E. , Wang Steven J. , Long Steven R. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

Supplementary Figure from STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer
Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

Increased T lymphocyte infiltration in the recurrent compared to the primary tumor. (A) CD3 immunohistochemical staining in the primary and recurrent tumor. (B) Three fields of view were selected and counted CD3+ T cells in both perivascular and peritumoral areas of the primary and recurrent tumors using ImageJ. Scale bars are indicated in the figures.
Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

Peripheral blood T cell responses to v-peptides increase with repetitive vaccination. (A) PBMCs were collected 3 weeks after the 2nd peptide cocktail vaccination, and CD45RA-negative PBMCs were stimulated with 4 μg/mL Tetanus toxoid, 2 μM CEF II peptide pool or 5 μM v-peptides for 7 days. 5-10 replicate wells were tested for proliferation, and proliferation measured by 3H-thymidine incorporation assay. CD45RA-negative PBMCs collected before vaccination were used as reference. The proliferation strength is depicted as stimulation index (SI). The red dotted line indicates a stimulatory response of SI = 2, and values above the red dotted line were considered positive. (#) indicates the peptide that was used in the vaccinations. (B) PBMCs were collected 5 weeks after the 3rd peptide cocktail vaccination, and CD45RA-negative PBMCs were stimulated with 4 μg/mL Tetanus toxoid, 2 μM CEF II peptide pool or 5 μM v-peptides for 7 days. 5-10 replicate wells were tested for proliferation, and proliferation was measured by 3H-thymidine incorporation assay. CD45RA-negative PBMCs collected before vaccination were used as the control. Data are expressed as mean ± SEM, and p values were determined using an unpaired t-test. * p < 0.05, ** p < 0.01, *** p < 0.001.
Supplementary Figure from Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus–Driven Cancers
Authors: Ghosh Soma , Mazumdar Tuhina , Xu Wei , Powell Reid T. , Stephan Clifford , Shen Li , Shah Pooja A. , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Frederick Mitchell J. , Johnson Faye M.
Published: April 2023

Supplementary Figure from Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus–Driven Cancers
Supplementary Figure S4 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Authors: Asleh Karama , Lluch Ana , Goytain Angela , Barrios Carlos , Wang Xue Q. , Torrecillas Laura , Gao Dongxia , Ruiz-Borrego Manuel , Leung Samuel , Bines José , Guerrero-Zotano Ángel , García-Sáenz Jose Ángel , Cejalvo Juan Miguel , Herranz Jesus , Torres Roberto , Haba-Rodriguez Juan de la , Ayala Francisco , Gómez Henry , Rojo Federico , Nielsen Torsten O. , Martin Miguel
Published: April 2023

Supplementary Figure S4 shows a forest plot of the exploratory categorical analysis of selected (meta)gene expression and their association with disease free survival on the capecitabine arm vs. observation.